Aktuellt
SENASTE
Gasporox beat our expectations by 34% on the top line with positive quarterly EBITDA. Strong sales and better gross margin resulted in a strong EBITDA beat. However, we are cautious about extrapolating the trend, and our initial view is that part of the strong quarter was due to consuming the existing order book. We will likely keep our fair value range.
LÄS MER
